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(anti-VEGF) were estimated based on prices established by Brazilian Drug Market 
Regulation Chamber. RESULTS: Nine studies were included: eight SR and one 
HTA. All reviews showed weak strength of recommendation and moderate to 
high quality of evidence. Sorafenib showed a median progression free-survival 
time around 6 months and was more effective than placebo, equally effective 
than interferon, and less effective than sunitinib. Patients who received 
sorafenib had a higher risk of suffering major adverse events. The cost of 
monthly treatment with anti-VEGF: sorafenib, sunitinib, temsirolimus, 
bevacizumab and interferon alpha was US$ 4.090,40, US$ 7.017,83, US$ 4.619,26, 
US$ 8.037,17 and US$ 3.166,67, respectively. CONCLUSIONS: Based on the 
available evidence, the increased survival caused by anti-VEGF is modest and 
based on weak evidence level, therefore with little clinical value. In addition, 
treatment with anti-VEGF is associated with serious adverse events and shows 
high cost. Hence we recommend the use of these drugs only when the surgical 
procedure isn’t indicated. All studies include patients with mCCR of clear cell, so 
it´s unclear whether the results can be extrapolated to patients with other stages 
and subtypes of RCC.  
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group  
45-65 years are the target population and 2 years screening interval is applied. 
The aim of this study is to evaluate the quality indicators of the 3rd screening 
round (2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated the following indicators: recall rate of women who 
underwent mammography examinations, attendance of re-called women, 
proportion of women referred to surgery, proportion of women who underwent 
surgery compared to referred women, proportion of benign and malign cases. 
RESULTS: In 2006-2007 there were 453142 screening mammography 
examinations in Hungary. 5.48% of participating women were re-called. The 
attendance of re-called women was 92.6%. Altogether 2087 women (9.6%) were 
referred for breast surgery but only 1503 women (72.0%) underwent surgery. 
Histological examination confirmed 379 benign (25.2%) and 1124 malign (74.8%) 
cases. CONCLUSIONS: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international 
professional guidelines. However, in addition to current indicators, new ones 
should be introduced in order to provide a more comprehensive monitoring of 
the program.  
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group 45-
65 years are the target population and 2 years screening interval is applied. The 
aim of this study is to analyze the attendance rate of the 3rd screening round 
(2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated two attendance indicators. The up-take of the program 
means the percentage of women aged 45-65 who, having been sent an invitation 
for screening, attend a screening unit and undergo mammography in response 
to that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic 
mammography. RESULTS: In 2006-2007 there were 453142 screening 
mammography cases and 1248183 diagnostic mammography examinations in 
Hungary. We found 41.7% and 52.5% up-take in 2006 and 2007 respectively; and 
46.3% combined rate for 2006/2007. The screening coverage was 29.2% and the 
diagnostic coverage was 21.6%, while the total coverage (screening and 
diagnostic) was 49.3%. CONCLUSIONS: The attendance of the Hungarian 
organized breast cancer screening program – compared to the previous period 
before the implementation of the organized screening program – is promising, 
although to achieve the expected results in mortality decrease a further 
improvement of both the uptake and coverage is necessary.  
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OBJECTIVES: To examine the impact of palonosetron versus other 5-HT3 RAs on 
incidence of delayed CINV at cycle 1 based on presence of certain risk factors 
(age <50 years, female gender, prior CINV, anxiety, no or minimal alcohol use, 
history of motion sickness, and emetogenicity of chemotherapy). METHODS: A 
retrospective claims analysis was conducted using OptumInsight database from 
December 1, 2005 to June 30, 2011. Continuously enrolled cancer patients >18 
years of age initiated on their first chemotherapy (index date) were included. 
Patients with a previous cancer diagnosis in the pre-index period or receiving 
multi-day chemotherapy were excluded. The study population was examined for 
differences in CINV rates by each 5-HT3 RA stratified by number of risk factors 
(female gender, age <50, previous anxiety, vomiting pre-index, and highly 
emetogenic chemotherapy. CINV was identified using ICD9CM codes for nausea, 
vomiting, or related events, and rescue medication use within 5 days after 
chemotherapy. RESULTS: Final analysis included 26,974 patients. Overall the 
percentage of patients experiencing CINV increased as the number of risk factors 
increased – 13.5%, 14.9%, 15.6%, and 18.4% for 0, 1, 2, and 3 or more risk factors, 
respectively. High-risk patients (3 or more risk factors) receiving palonosetron 
had less CINV events compared to ondansetron, granisetron, and dolasetron. 
Odds Ratios (OR) 95%CI versus palonosetron were 1.523 (1.231, 1.883), 1.426 
(1.146, 1.773), and 1.683 (1.271, 2.229), respectively. CONCLUSIONS: The 
probability of a CINV event increased with the accumulation of identified risk 
factors. Palonosetron demonstrated a statistically significant OR versus all other 
5-HT3 RA in patients at the highest risk of developing a CINV event.  
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OBJECTIVES: BTZ is administered for a finite course; thus, MM pts may remain 
sensitive to BTZ-based therapy at relapse. We conducted a meta-analysis to 
assess efficacy and safety of BTZ-based retreatment in studies of pts with 
relapsed (rel) and/or refractory (ref) MM. METHODS: The proportion of BTZ-ref 
pts was identified where available. Other prognostic factors were extracted and 
used in weighted stratified analyses of TTP, PFS, and OS. Random-effect pooled 
estimates were calculated for ORR (≥PR) and rates of common AEs. RESULTS: 
Twenty-three studies (N=1051 pts) were identified. BTZ was given IV in all 
studies. Retreatment comprised BTZ±dex in 4 studies and BTZ-based 
combination therapy in 19. BTZ-ref pts were included in 11 studies; 6 studies 
included only rel pts. Across studies with data available, pooled, weighted 
average ORR was 39% (95% CI: 31–47) and median TTP, PFS, and OS were 7.5, 5.8, 
and 16.6 months. Stratified univariate analyses showed outcomes were generally 
consistent across groups while pts with ≤4 prior therapies and rel (but not ref) 
pts had higher ORRs of 43% and 57%, respectively. By random-effects meta-
regression analysis, compared to ref pts, rel pts were associated with a higher 
ORR by 28–41 percentage points. The most common grade 3/4 AEs were 
thrombocytopenia (35%), neutropenia (15%), anemia (14%), pneumonia (10%), and 
peripheral neuropathy (3%). CONCLUSIONS: Based on these findings, BTZ 
retreatment is efficacious and well tolerated in rel pts. In an era of new and 
emerging treatment options, these data indicate BTZ retreatment continues to 
be a highly effective option in previously treated pts.  
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BACKGROUND: Prior to the March 25, 2011 FDA-approval of ipilimumab (ipi), 
clinical trial data indicated that no drug treatment (tx) for advanced melanoma 
(AM) (unresectable or metastatic melanoma) led to an improvement in overall 
survival (OS). OBJECTIVES: To further explore the relationship between OS and 
the treatments available for AM patients prior to ipi approval by examining real 
world (RM) data. METHODS: Baseline characteristics, tx and outcomes of 752 
newly diagnosed AM pts (2004-2008) were collected from the medical charts of a 
nationally representative random sample of 113 U.S. oncologists. Follow-up of 
survival outcomes concluded on the date of ipi approval. OS from AM diagnosis 
to 1 and 2 years were described by stage and by whether pts were incident (no 
prior melanoma) or recurrent (AM diagnosis after early-stage melanoma). To 
determine change in outcomes over time, current OS of incident pts was 
compared to published data on a prior cohort of pts from the AJCC registry, 
staged at initial melanoma diagnosis (Balch 2001). RESULTS: One-year (39.8%, 
95% CI=[34.2-45.3%]) and 2-year (27.6%, 95% CI=[22.4-32.8%]) survival rates among 
incident Stage IV pts were statistically similar to weighted averages (by 
metastasis classification) from the AJCC registry. Incident unresectable Stage III 
pts had lower OS rates than the weighted average of all Stage III pts from the 
AJCC registry (which included both resectable and unresectable pts). 
CONCLUSIONS: These real-world data show that incident metastatic melanoma 
pts diagnosed from 2004 to 2008 had OS similar to the AJCC registry pts—who 
were diagnosed in prior decades—and confirm the limitations of AM tx prior to 
ipi approval. Future research should examine OS in real-world AM pts following 
ipi approval.  
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OBJECTIVES: Colon cancer (CC) is primarily a disease of older individuals, with 
65.3% of incident cases in the United States occurring in those aged 65 and 
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above. There is uncertainty, however, regarding the effectiveness of oxaliplatin 
in combination adjuvant chemotherapy for prevention of mortality in this 
population. Oxaliplatin’s rapid adoption for treatment of stage III colon cancer 
patients in 2004 provides an opportunity to use calendar time as an instrumental 
variable (IV) in nonexperimental comparative effectiveness research. This 
method makes assumptions different from covariate adjustment and may thus 
enhance our understanding of treatment effects. METHODS: We examined 
patients aged 65+ initiating chemotherapy between 2003-08 using population-
based cancer registry data linked with Medicare claims (N=3660). We derived risk 
of all-cause mortality from Kaplan-Meier survival curves and estimated risk 
differences (RD). We examined IV strength and compared RDs with propensity 
score (PS)-matched estimates. RESULTS: Calendar time greatly affected 
treatment receipt. The optimal 2-level calendar time instrument achieved a 
strength of 53.97% compliance by grouping patients treated from January 2003 
through September 2004 (n=1449) and those treated from March 2005 through 
May 2007 (n=1432). The 1-,2-,3-year Wald IV RDs (95% confidence interval) were  
-0.05 (-0.09, -0.01), -0.07 (-0.12, -0.01), -0.09 (-0.15, -0.03), respectively. PS-adjusted 
1-,2-,3-year RDs were -0.02(-0.04,0), -0.03(-0.06,-0.01), -0.04(-0.08,-0.01). 
CONCLUSIONS: IV and PS-adjusted models both indicate a survival advantage in 
this population of older patients treated with oxaliplatin, albeit with different 
point estimates. As these RDs are based on different assumptions and apply to 
different populations, the IV analysis strengthens evidence of oxaliplatin’s 
effectiveness in older adults, who bear the greatest burden of colon cancer yet 
were underrepresented in oxaliplatin clinical trials. In nonexperimental CER of 
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OBJECTIVES: Since the 1970s, cancer incidence and mortality have been 
increasing rapidly in China. The purpose of this study was to project cancer 
incidence of the fourteen major cancers in China from 2010 to 2030 by evaluating 
the potential effects of the population growth, change in age structure, and 
urbanization. METHODS: A demographic approach was taken for projection. 
Cancer incidence rates, projected populations, and urbanization rates were 
obtained or derived based on the database from the Chinese cancer registry 
office, the U.S. census bureau, and the Department of Economic and Social 
Affairs of the United Nations, respectively. Incidence rates and population data 
were categorized by area (rural vs urban), gender (male vs female), and age  
(5-year age groups). Cancer incidence was projected by applying the area-, 
gender-, and age-specific incidence rates of each cancer to the corresponding 
subpopulations in 2010, and 2030 respectively. The fourteen tumor types 
included cancers of the bladder, breast, cervix, colorectum, esophagus, head and 
neck, kidney, liver, lung, melanoma, ovary, pancreas, prostate, and stomach. 
RESULTS: Compared with 2010, the incidence of the fourteen major cancers in 
China will increase by 64.3% in 2030 from 2.6 million to 4.3 million. The urban 
incidence population and the senior incidence population (>=65 years old) will be 
more than doubled (from 1.1 to 2.5 million, and 1.2 to 2.5 million respectively). 
The top five cancers (lung, stomach, liver, esophagus, and colorectum) accounted 
for more than 77.5% of the fourteen major cancers in 2010, and they will increase 
by 55.8% from 2.2 million to 3.5 million in 2030. Cancers of the prostate, bladder, 
colorectum, pancreas, and lung are among the fastest growing cancers. 
CONCLUSIONS: The aging population and the accelerated urbanization trend in 
China will drastically increase cancer incidence in the near future, and this will 
impose a significant economic burden on the health care system.  
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OBJECTIVES: Surgical outcomes are associated with patient and surgeon 
characteristics. If outcomes are also independently impacted by the specific 
hospital where the surgery occurs, there is a hospital center effect (HCE). This 
study is to examine HCE among elderly stage l-lll colon cancer patients with 
laparoscopic colectomies. METHODS: The Surveillance, Epidemiology and End 
Results (SEER)-Medicare dataset was used to identify stage I-III colon cancer 
patients in 2003 to 2007 with laparoscopic colectomies. Multilevel model 
regressions were utilized to study potential HCE for length of stay (LOS), 30-day 
re-hospitalization, and in-hospital mortality, adjusting for patient, surgeon and 
hospital level characteristics. To quantify the impact of HCE, we calculated 
median instantaneous rate ratio (MIRR) for LOS and median odds ratio (MOR) for 
in-hospital mortality and 30-day re-hospitalization. Sensitivity analyses were 
also conducted for high volume/medical school affiliated hospitals and colorectal 
surgeons. RESULTS: The multilevel analyses based on 4,617 patients from 465 
hospitals documented significant HCEs for LOS (MIRR = 1.36; p < 0.001) and in-
hospital mortality (MOR=1.72; p=0.037), but no HCE for 30-day re-hospitalization. 
For patients with Charlson comorbidity index (CCI) greater than or equal to 3, 
MIRR rose to 2.27 for LOS and MOR rose to 6.87 for in-hospital mortality, as 
compared to patients with CCI = 1. The sensitivity analyses confirmed our 
findings. HCE was significant for LOS in all subgroup analyses, and was 
significant for in-hospital mortality for high volume/medical school affiliated 
hospitals. CONCLUSIONS: HCE is an important source of variation for 
laparoscopy outcomes, and it is still significant when patient, provider and 
hospital level characteristics are adjusted. HEC exists for both LOS and in-
hospital mortality. The findings are robust to high volume/medical school 
affiliated hospitals and colorectal surgeons. HCE is a potential area to improve 
the quality of care for stage I-III laparoscopic colon cancer patients.  
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OBJECTIVES: To determine the impact of body mass index (BMI) on prognosis for 
patients with breast cancer. METHODS: Electronic medical records from a 
network of 9 hospitals were linked to female breast cancer patients who were 
diagnosed between 2007 and 2010 in Florida. Cox proportional hazards model 
was used to assess cause-specific survival. RESULTS: A total of 1368 patients 
with the diagnosis of breast cancer were identified. African American patients 
comprised 9.02%. Median follow-up time for those who died due to breast cancer 
was 709 days. Two-year survival was 94.7%. Overweight or obese patients were 
not significantly different from patients of normal weight in breast cancer 
survival. Breast cancer death rate for underweight patients was 2.1 times that of 
normal weight patients (p = 0.038). The proportion of underweight patients 
among those who died due to breast cancer was 13.21%, the highest compared to 
those in other groups. Multivariable analysis revealed an increased hazard 
associated with low BMI, triple negative biomarker status, distant stage, larger 
tumors, more positive nodes identified, and Medicare users. Lower hazard of 
breast cancer death was associated with more nodes examined. CONCLUSIONS: 
Underweight is associated with poorer prognosis in breast cancer patients. 
Neither overweight nor obese groups was associated with a significantly altered 
risk of breast cancer death following diagnosis. Mechanisms to understand the 
poorer prognosis for underweight patients need to be defined. Findings of this 
study suggest that weight management for underweight breast cancer patients 
and increase body weight to normal weight may deserve examination.  
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OBJECTIVES: Optimal therapy and associated survival benefit for patients with 
stages IIIB/C and IV colorectal cancer (CRC) have not been well established. The 
aim of this study was to examine treatment patterns and survival among CRC 
patients who received 2nd and 3rd line regimens. METHODS: A retrospective 
analysis was performed using the Georgia Cancer Specialist Database. Patients 
18 years and older diagnosed with stage IIIB/C or IV CRC between January, 2006 
and November, 2012 were followed from initial CRC diagnosis until death, study 
end or loss to follow-up. Regimen concordance with National Comprehensive 
Cancer Network (NCCN) treatment guidelines was assessed. Survival was 
compared between patients who initiate second- versus third-line regimens 
using Cox proportional hazards models. RESULTS: 1081 patients were identified, 
542 with stage IIIB/C and 539 with stage IV CRC. The most common first line 
regimens were FOLFOX (32% of patients) and FOLFOX with bevacizumab (18% of 
patients). In discordance with the NCCN guidelines, 16% of patients received 
monotherapy as first line. 544 patients (50%) received second line therapy; the 
most common regimen was bevacizumab plus IFL (14% of patients who received 
second line therapy). Approximately 25% of patients (n=269) received third line 
therapy. The most common therapies were irinotecan/cetuximab, bevacizumab 
monotherapy, and capecitabine monotherapy (10% of 3rd line patients, 
respectively). 73% of 3rd line patients had ECOG performance scores of zero or 
one. Survival was significantly worse in stage IV patients who received 3rd line 
therapy versus those who stopped at 2nd line (p=0.004). CONCLUSIONS: Most 
patients received treatment in accordance with NCCN guidelines; however, a 
substantial proportion received monotherapy as first line. There was no survival 
benefit observed in stage IV patients who began a third line therapy. The 
subpopulation of patients who may benefit from 3rd line therapy should be 
explored in future studies.  
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OBJECTIVES: To describe patient characteristics and survival in a cohort of 
commercially insured individuals with incident malignant brain tumors. 
METHODS: The Truven Health Analytics MarketScan Research Databases were 
used to identify adults with incident malignant neoplasm of the brain (191.xx) 
who underwent brain surgery (index event) during 2006-2010. Patients were 
required to have 6 months of continuous enrollment prior to the index surgery 
and were excluded if they received chemotherapy, temozolomide, or brain 
surgery or had another primary or secondary cancer during the pre-index period. 
Eligible patients were then linked to the Social Security Administration (SSA) 
master death files. The SSA death files indicate the presence and date of death. 
The combined dataset was used to describe patient characteristics, post-surgery 
